0
0

TRANQ Research Act of 2023

12/21/2023, 2:13 PM

Summary of Bill HR 1734

The TRANQ Research Act of 2023, also known as Bill 118 hr 1734, is a piece of legislation currently being considered by the US Congress. The main purpose of this bill is to establish a program within the National Institutes of Health (NIH) to research the potential therapeutic uses of psychedelic substances, such as psilocybin and MDMA, for treating mental health conditions.

The bill aims to address the growing interest in the potential benefits of psychedelic therapy for conditions such as depression, PTSD, and anxiety. It would allocate funding for research studies to investigate the safety and efficacy of these substances, as well as their potential mechanisms of action in the brain.

Additionally, the TRANQ Research Act of 2023 includes provisions to ensure that research on psychedelic substances is conducted in a safe and ethical manner. This includes requirements for obtaining appropriate licenses and permits, as well as guidelines for protecting the rights and well-being of research participants. Overall, the bill seeks to advance scientific understanding of the therapeutic potential of psychedelic substances and pave the way for their potential integration into mainstream mental health treatment options. It represents a significant step forward in the field of psychedelic research and has the potential to impact the lives of individuals struggling with mental health conditions.

Congressional Summary of HR 1734

Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023 or the TRANQ Research Act of 2023

This bill requires the National Institute of Standards and Technology (NIST) to support research and other activities related to identifying xylazine (a compound used in veterinary medicine as a nonopioid tranquilizer), novel synthetic opioids, and other new psychoactive substances.

In particular, NIST must support

  • basic measurement science and research;
  • near-real time spectrometry capabilities (i.e., a technique for rapidly identifying the chemical composition of a substance);
  • strategies and voluntary best practices for handling, transporting, and analyzing such substances; and
  • collaboration with other government agencies, institutions of higher education, and the private sector to enhance relevant narcotic and opioid detection and analysis capabilities.

Additionally, the Government Accountability Office must conduct a study on the capabilities of the federal government to detect, identify, and otherwise respond to threats of new psychoactive substances, such as xylazine.

Current Status of Bill HR 1734

Bill HR 1734 is currently in the status of Signed by President since December 19, 2023. Bill HR 1734 was introduced during Congress 118 and was introduced to the House on March 23, 2023.  Bill HR 1734's most recent activity was Became Public Law No: 118-23. as of December 19, 2023

Bipartisan Support of Bill HR 1734

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
50
Democrat Cosponsors
26
Republican Cosponsors
24
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 1734

Primary Policy Focus

Science, Technology, Communications

Potential Impact Areas

- Advanced technology and technological innovations
- Chemistry
- Congressional oversight
- Drug trafficking and controlled substances
- Higher education
- Research administration and funding
- Science and engineering education

Alternate Title(s) of Bill HR 1734

TRANQ Research Act of 2023
Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023
TRANQ Research Act of 2023
TRANQ Research Act
Testing, Rapid Analysis, and Narcotic Quality Research Act
TRANQ Research Act
Testing, Rapid Analysis, and Narcotic Quality Research Act
TRANQ Research Act
Testing, Rapid Analysis, and Narcotic Quality Research Act
To require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.

Comments